Human CD30/TNFRSF8 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 81337

Catalog Number: FAB229P

100 TESTS

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CD30/TNFRSF8 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse CD30, recombinant human (rh) CD27, and rhCD40 is observed.
Source	Monoclonal Mouse IgG_{2B} Clone # 81337
Purification	Protein A or G purified from ascites
Immunogen	*S. frugiperda* insect ovarian cell line *Sf* 21-derived recombinant human CD30/TNFRSF8 Phe19-Lys379 Accession # P28908
Conjugate	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: *Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.*

	Recommended Concentration	Sample
Flow Cytometry	10 µL/10^6 cells	See Below

DATA

Flow Cytometry



Detection of CD30/TNFRSF8 in Jurkat Human Cell Line by Flow Cytometry. Jurkat human acute T cell leukemia cell line was stained with Mouse Anti-Human CD30/TNFRSF8 PE-conjugated Monoclonal Antibody (Catalog # FAB229P, filled histogram) or isotype control antibody (Catalog # IC0041P, open histogram). View our protocol for Staining Membrane-associated Proteins.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Protect from light. Do not freeze.** • 12 months from date of receipt, 2 to 8 °C as supplied.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956

Human CD30/TNFRSF8 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 81337

Catalog Number: FAB229P

100 TESTS

BACKGROUND

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C-terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

References:

1. Kennedy, M.K. *et al.* (2006) Immunology **118**:143.
2. Tarkowski, M. (2003) Curr. Opin. Hematol. **10**:267.
3. Durkop, H. *et al.* (1992) Cell **68**:421.
4. Hamann, D. *et al.* (1996) J. Immunol. **156**:1387.
5. Shanebeck, S.D. *et al.* (1995) Eur. J. Immunol. **25**:2147.
6. Gruss, H.-J. *et al.* (1994) Blood **83**:2045.
7. Oflzoglu E. *et al.* (2009) Adv. Exp. Med. Biol. **647**:174.
8. Del Prete, G. *et al.* (1995) J. Exp. Med. **182**:1655.
9. Harlin, H. *et al.* (2002) J. Immunol. **169**:2451.
10. Amakawa, R. *et al.* (1996) Cell **84**:551.
11. Chiarle, R. *et al.* (1999) J. Immunol. **163**:194.
12. Vinante, F. *et al.* (2002) Blood **99**:52.
13. Hansen, H.P. *et al.* (1995) Int. J. Cancer **63**:750.
14. Hansen, H.P. *et al.* (2000) J. Immunol. **165**:6703.
15. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. **32**:163.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956